
Initial data from a phase 1/2 trial of Beam Therapeutics' BEAM-302, a first-in-human in vivo base-editing therapy for AATD, showed a single dose durably raised functional AAT above the protective threshold at #ERS2026, according to @ProfHurst Watch now: hcplive.com/view/beam-302-ba…




























